Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 8/20 | 0.68 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | GALR3 | O60755 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2250255 | 1.00 | ADRB3 (0.68) | ADRB3ADRB2LMNAHIF1ASLC6A2 | |
| SCHEMBL14307655 | 1.00 | ADRB3 (0.68) | ADRB3ADRB2LMNAHIF1ASLC6A2 | |
| Hydrochloric Acid SCHEMBL4608896 | 0.99 | ADRB3 (0.68) | ADRB3ADRB2LMNAHIF1ASLC6A2 | |
| Hydrochloric Acid SCHEMBL2250378 | 0.99 | ADRB3 (0.68) | ADRB3ADRB2LMNAHIF1ASLC6A2 | |
| SCHEMBL6814366 | 0.92 | ADRB3 (0.75) | ADRB3ADRB2LMNAHIF1ASLC6A2 | |
| SCHEMBL6814376 | 0.92 | ADRB3 (0.75) | ADRB3ADRB2LMNAHIF1ASLC6A2 | |
| Ritobegron SCHEMBL1404071 | 0.89 | ADRB3 (0.64) | ADRB3ADRB2LMNAHIF1ASLC6A2 | |
| Ritobegron SCHEMBL5916906 | 0.89 | ADRB3 (0.64) | ADRB3ADRB2LMNAHIF1ASLC6A2 | |
| SCHEMBL13653975 | 0.89 | ADRB3 (0.54) | ADRB3ADRB2LMNAHIF1ASLC6A2 | |
| Ritobegron SCHEMBL1404072 | 0.89 | ADRB3 (0.64) | ADRB3ADRB2LMNAHIF1ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620085-B1 | USE OF PHENOXYACETIC ACID DERIVATIVES FOR TREATING HYPERACTIVE BLADDER | KISSEI PHARMACEUTICAL (JP) | 2008-07-23 | — | — | EP | claimed |
| EP-1620085-A1 | USE OF PHENOXYACETIC ACID DERIVATIVES FOR TREATING HYPERACTIVE BLADDER | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-02-01 | — | — | EP | claimed |
| WO-2004098586-A1 | USE OF PHENOXYACETIC ACID DERIVATIVES FOR TREATING HYPERACTIVE BLADDER | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | WO | claimed |
| EP-1095932-B1 | PHENOXYACETIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | KISSEI PHARMACEUTICAL (JP) | 2004-05-19 | — | — | EP | claimed |
| US-20100197788-A9 | Preventive or therapeutic agent for disease caused by decrease in lacrimal fluid | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20080306160-A1 | Preventive or therapeutic agent for disease caused by decrease in lacrimal fluid | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| EP-1620085-B1 | USE OF PHENOXYACETIC ACID DERIVATIVES FOR TREATING HYPERACTIVE BLADDER | KISSEI PHARMACEUTICAL (JP) | 2008-07-23 | — | — | EP | disclosed |
| EP-1938837-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR DISEASE CAUSED BY DECREASE IN LACRIMAL FLUID | Kissei Pharmaceutical Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-1620085-A1 | USE OF PHENOXYACETIC ACID DERIVATIVES FOR TREATING HYPERACTIVE BLADDER | Kissei Pharmaceutical Co., Ltd. (JP) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004098586-A1 | USE OF PHENOXYACETIC ACID DERIVATIVES FOR TREATING HYPERACTIVE BLADDER | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | WO | disclosed |
| US-20040229947-A1 | Method of treating hyperactive bladder using phenoxyacetic acid derivatives | KISSEI PHARMACEUTICAL CO., LTD. | 2004-11-18 | — | — | US | disclosed |
| EP-1095932-B1 | PHENOXYACETIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | KISSEI PHARMACEUTICAL (JP) | 2004-05-19 | — | — | EP | disclosed |
| US-6538152-B1 | Obesity, hyperglycemia, urinary incontinence, intestinal or biliary calculi hypermotility, pollakiuria and depression treatment | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2003-03-25 | — | — | US | disclosed |
| EP-1095932-A1 | PHENOXYACETIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2001-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229947-A1 | Method of treating hyperactive bladder using phenoxyacetic acid derivatives | BPHL, HTR5A, PNMT | ADRB3 123/4885ADRB2 96/4885LMNA 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.